We narrowed to 1,077 results for: FIE

#162381-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-CAG-FLEX-jGCaMP8m-WPRE (#162381). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP8m-WPRE plasmid DNA. CAG-driven, Cre-dependent expression of calcium sensor GCaMP8m (faster, more sensitive). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Feb. 7, 2025

Academic Institutions and Nonprofits only

#104488-AAV9

Ready-to-use AAV9 particles produced from pGP-AAV-syn-jGCaMP7f-WPRE (#104488). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7f-WPRE plasmid DNA. Synapsin-driven GCaMP7f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

March 22, 2018

Academic Institutions and Nonprofits only

#65014-AAV5

Ready-to-use AAV5 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Feb. 7, 2018

Academic Institutions and Nonprofits only

#162379-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-FLEX-jGCaMP8f-WPRE (#162379). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP8f-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the ultrafast calcium sensor, GCaMP8f. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

Dec. 3, 2020

Academic Institutions and Nonprofits only

#107312-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-mCherry-P2A-Cre-WPRE (#107312). In addition to the viral particles, you will also receive purified AAV-hSyn-mCherry-P2A-Cre-WPRE plasmid DNA. hSyn-driven expression of mCherry and Cre (physically separate). These AAV preparations are suitable purity for injection into animals.

Hui Yang

Zhou et al Nat Neurosci. 2018 Jan 15. pii: 10.1038/

Oct. 28, 2021

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#100799-AAV1

Ready-to-use AAV1 particles produced from pAAV-TREtight-mTagBFP2-B19G (#100799). In addition to the viral particles, you will also receive purified pAAV-TREtight-mTagBFP2-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-syn-FLEX-splitTVA-EGFP-tTA (Addgene# 100798). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#100798-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-FLEX-splitTVA-EGFP-tTA (#100798). In addition to the viral particles, you will also receive purified pAAV-syn-FLEX-splitTVA-EGFP-tTA plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-TREtight-mTagBFP2-B19G (Addgene#100799). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#65417-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-dF-HA-KORD-IRES-mCitrine (#65417). In addition to the viral particles, you will also receive purified pAAV-hSyn-dF-HA-KORD-IRES-mCitrine plasmid DNA. hSyn-driven, Cre-dependent KORD expression with bicistronic mCitrine, for SALB-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Vardy et al Neuron. 2015 Apr 29. pii: S0896-6273(15)

Oct. 26, 2017

Academic Institutions and Nonprofits only

#137141-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Coff/Fon-ChR2(ET/TC)-EYFP (#137141). In addition to the viral particles, you will also receive purified pAAV-nEF-Coff/Fon-ChR2(ET/TC)-EYFP plasmid DNA. nEF-driven, Flp-dependent expression of ChR2(E123T/T159C)-EYFP (inhibited in presence of Cre) for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#92379-LV

Ready-to-use Lentiviral Prep particles produced from Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (#92379). In addition to the viral particles, you will also receive purified Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A plasmid DNA. Ready-to-use lentiviral pooled library for CRISPR activation screening in human cells. Contains 56,762 sgRNAs, targeting 18,885 genes. Concentrated lentiviral particles carrying set A of the Calabrese human CRISPRa sgRNA activation library in backbone XPR_502 (P65 HSF) .

John Doench, David Root

Sanson et al Nat Commun. 2018 Dec 21;9(1):5416. doi:

Aug. 3, 2017

Academic Institutions and Nonprofits only

#55645-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

June 8, 2020

Academic Institutions and Nonprofits only

#137134-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-mCherry (#137134). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-mCherry plasmid DNA. EF1a-driven, Flp-dependent expression of mCherry (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 23, 2021

Academic Institutions and Nonprofits only

#83895-AAV2

Ready-to-use AAV2 particles produced from pAAV-hDlx-Flex-GFP-Fishell_6 (#83895). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-GFP-Fishell_6 plasmid DNA. hDlx-driven, Cre-dependent expression of GFP. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Jan. 6, 2022

Academic Institutions and Nonprofits only

#83897-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-GqDREADD-dTomato-Fishell-4 (#83897). In addition to the viral particles, you will also receive purified pAAV-hDlx-GqDREADD-dTomato-Fishell-4 plasmid DNA. hDlx-driven expression of GqDREADD (hM3D) and nuclear localized dTomato (physically separate) for activation of interneurons. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#55645-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn Con/Fon hChR2(H134R)-EYFP (#55645). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon hChR2(H134R)-EYFP plasmid DNA. Synapsin-driven, Cre-dependent and Flp-dependent channelrhodopsin-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 2, 2019

Academic Institutions and Nonprofits only

#51502-AAV8

Ready-to-use AAV8 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre-dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Jan. 26, 2021

Academic Institutions and Nonprofits only

#130909-AAV8

Ready-to-use AAV8 particles produced from AAV-CAG-FLPX-rc [ChrimsonR-tdTomato] (#130909). In addition to the viral particles, you will also receive purified AAV-CAG-FLPX-rc [ChrimsonR-tdTomato] plasmid DNA. CAG-driven, Flp-dependent expression of ChrimsonR-tdTomato. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#101060-AAV1

Ready-to-use AAV1 particles produced from pAAV_hsyn_NES-his-CaMPARI2-WPRE-SV40 (#101060). In addition to the viral particles, you will also receive purified pAAV_hsyn_NES-his-CaMPARI2-WPRE-SV40 plasmid DNA. Synapsin-driven, photoconvertible (irreversible green-to-red) calcium integrator his-tagged CaMPARI2. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Moeyaert et al Nat Commun. 2018 Oct 25;9(1):4440. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#104488-AAV8

Ready-to-use AAV8 particles produced from pGP-AAV-syn-jGCaMP7f-WPRE (#104488). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7f-WPRE plasmid DNA. Synapsin-driven GCaMP7f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

May 29, 2019

Academic Institutions and Nonprofits only